David A. Siegel Vir Biotechnology, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 504,000 shares of VIR stock, worth $2.84 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
504,000
Previous 314,900
60.05%
Holding current value
$2.84 Million
Previous $1.59 Million
81.29%
% of portfolio
0.01%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding VIR
# of Institutions
243Shares Held
106MCall Options Held
246KPut Options Held
126K-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$93.9 Million0.72% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$92.5 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL12.9MShares$72.7 Million32.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$72.1 Million0.0% of portfolio
-
State Street Corp Boston, MA5.24MShares$29.5 Million0.0% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $747M
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...